title: [Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis].
abstract: OBJECTIVE
  To investigate the efficacy and safety of polysaccharide nucleic acid-fraction (BCG-PSN) in the treatment of vasomotor rhinitis.
  
  
  METHODS
  Sixty patients were randomly divided into BCG-PSN group (n = 30) and control group (n = 30). The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months, and intranasal azelastine was used if needed. The patients in control group were administered with intranasal azelastine solely twice a day, which could be decreased with the symptom relief. Follow-up was 6 months. Symptom and medication scores were recorded. Side effects were registered.
  
  
  RESULTS
  The symptom and medication scores of BCG-PSN group were significantly lower than that of control group (P < 0.01) after BCG-PSN treatment. There was no significant difference in symptom score between the two groups at 6 months after BCG-PSN treatment (P > 0.05), while the medication score of BCG-PSN group was still much lower than that of control group (P < 0.01). No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.
  
  
  CONCLUSIONS
  BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.
authors.affiliation: Department of Otorhinolaryngology, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. jj-c@tom.com
authors.forename: Jianjun
authors.initials: J
authors.lastname: Chen
authors.forename: Weijia
authors.initials: W
authors.lastname: Kong
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhou
authors.forename: Jisheng
authors.initials: J
authors.lastname: Xiang
authors.forename: Hong
authors.initials: H
authors.lastname: Shu
authors.forename: Qiumei
authors.initials: Q
authors.lastname: Shi
authors.forename: Huifang
authors.initials: H
authors.lastname: Tan
mesh_terms: D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012223:Rhinitis, Vasomotor / Q000188:drug therapy*; D016037:Single-Blind Method; D055815:Young Adult
chemical_list: D001500:BCG Vaccine